CR20180592A - Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos - Google Patents
Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativosInfo
- Publication number
- CR20180592A CR20180592A CR20180592A CR20180592A CR20180592A CR 20180592 A CR20180592 A CR 20180592A CR 20180592 A CR20180592 A CR 20180592A CR 20180592 A CR20180592 A CR 20180592A CR 20180592 A CR20180592 A CR 20180592A
- Authority
- CR
- Costa Rica
- Prior art keywords
- lrrk2
- inhibitors
- pirazoles
- pirimidin
- ilamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350876P | 2016-06-16 | 2016-06-16 | |
| US201662417151P | 2016-11-03 | 2016-11-03 | |
| US201762476581P | 2017-03-24 | 2017-03-24 | |
| US201762510711P | 2017-05-24 | 2017-05-24 | |
| PCT/US2017/037782 WO2017218843A1 (en) | 2016-06-16 | 2017-06-15 | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180592A true CR20180592A (es) | 2019-03-05 |
Family
ID=59216078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180592A CR20180592A (es) | 2016-06-16 | 2017-06-15 | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos |
| CR20220182A CR20220182A (es) | 2016-06-16 | 2017-06-15 | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220182A CR20220182A (es) | 2016-06-16 | 2017-06-15 | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) |
Country Status (37)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| PT3472153T (pt) | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| SG11202004733WA (en) * | 2017-11-21 | 2020-06-29 | Denali Therapeutics Inc | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
| IL275480B2 (en) | 2017-12-20 | 2023-10-01 | Denali Therapeutics Inc | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| KR20190131981A (ko) * | 2018-05-18 | 2019-11-27 | 재단법인 대구경북첨단의료산업진흥재단 | 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물 |
| AR118641A1 (es) | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| KR20220015437A (ko) * | 2019-05-31 | 2022-02-08 | 데날리 테라퓨틱스 인크. | 피리미디닐아미노-피라졸 화합물의 변형 방출 제제, 및 치료 방법 |
| EP3769768A1 (en) | 2019-07-23 | 2021-01-27 | Consejo Superior de Investigaciones Cientificas (CSIC) | Compounds useful for the treatment of parkinson s disease |
| UY38934A (es) * | 2019-10-29 | 2021-05-31 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
| CA3172750A1 (en) | 2020-03-23 | 2021-09-30 | Ge Hyeong Lee | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
| KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| ES3019615T3 (en) * | 2020-10-07 | 2025-05-20 | Alzprotect | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders |
| KR20230091150A (ko) * | 2020-10-29 | 2023-06-22 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
| WO2022232487A1 (en) * | 2021-04-30 | 2022-11-03 | Denali Therapeutics Inc. | Methods for treating and monitoring parkinson's disease |
| WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| MX2024007383A (es) | 2021-12-15 | 2024-08-28 | Whan In Pharmaceutical Co Ltd | Derivado de pirimidina macrocíclica, método para preparar el mismo y composición farmacéutica para prevención o tratamiento de una enfermedad neurodegenerativa que contiene el mismo como ingrediente activo. |
| CN117624185B (zh) * | 2022-08-23 | 2025-12-05 | 长春金赛药业有限责任公司 | Lrrk2抑制剂化合物、药物组合物及其制备方法和应用 |
| TW202412777A (zh) | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
| CN120826397A (zh) | 2022-11-03 | 2025-10-21 | 戴纳立制药公司 | 嘧啶三唑化合物的固体及共晶体形式 |
| CN115894456A (zh) * | 2022-11-13 | 2023-04-04 | 药康众拓(江苏)医药科技有限公司 | 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途 |
| TW202434571A (zh) | 2022-11-22 | 2024-09-01 | 美商戴納立製藥公司 | 嘧啶胺基吡唑化合物之製備方法及中間物 |
| CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
| WO2025051214A1 (zh) * | 2023-09-07 | 2025-03-13 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法 |
| CN118878521B (zh) * | 2024-09-26 | 2025-02-14 | 苏州美诺医药科技有限公司 | 一种lrrk2抑制剂的制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| AU2002339230A1 (en) | 2002-03-08 | 2003-09-22 | Decode Genetics Ehf. | A susceptibility gene for late-onset idiopathic parkinson's disease |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| AR049418A1 (es) | 2004-02-27 | 2006-08-02 | Bayer Pharmaceuticals Corp | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. |
| WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| EP1999135A2 (en) | 2006-03-30 | 2008-12-10 | Takeda San Diego, Inc. | Kinase inhibitors |
| BRPI0713738A2 (pt) | 2006-06-20 | 2014-06-24 | Novartis Ag | Biomarcadores para a progressão de doença alzheimer |
| WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2008128968A1 (en) | 2007-04-19 | 2008-10-30 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 |
| JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
| AU2008257044A1 (en) | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| AR075713A1 (es) | 2009-03-03 | 2011-04-20 | Du Pont | Pirazoles fungicidas |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| EP2498607B1 (en) | 2009-11-13 | 2016-02-17 | Genosco | Kinase inhibitors |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| MX2012014158A (es) | 2010-06-04 | 2013-02-07 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2). |
| US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
| WO2012058193A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| PH12013500880A1 (en) * | 2010-11-10 | 2013-07-01 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| CN103348243A (zh) | 2010-11-30 | 2013-10-09 | 基因泰克公司 | Lrrk2的分析方法和生物标记物 |
| US20140170157A1 (en) | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| US20140179664A1 (en) | 2011-07-28 | 2014-06-26 | Cellzome Limited | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors |
| AU2012311184A1 (en) | 2011-09-22 | 2014-03-06 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| KR102002198B1 (ko) | 2011-11-29 | 2019-07-19 | 제넨테크, 인크. | Lrrk2 조절제로서의 아미노피리미딘 유도체 |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| DK2785711T3 (en) | 2011-11-29 | 2016-09-05 | Hoffmann La Roche | 2- (phenyl or pyrid-3-yl) aminopyrimidine derivatives AS KINASE LRRK2 modulators for the treatment of Parkinson's disease |
| CN106349234A (zh) | 2011-11-29 | 2017-01-25 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| BR112014012822A8 (pt) | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
| WO2013126283A1 (en) | 2012-02-20 | 2013-08-29 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
| AR090220A1 (es) | 2012-03-01 | 2014-10-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| KR102091895B1 (ko) * | 2012-05-03 | 2020-04-14 | 제넨테크, 인크. | 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
| JP6218808B2 (ja) | 2012-05-03 | 2017-10-25 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体 |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| US9624180B2 (en) | 2013-01-25 | 2017-04-18 | Bristol-Myers Squibb Company | Squaric derivatives for the treatment of hepatitis C |
| EP3010908A1 (en) | 2013-02-20 | 2016-04-27 | E. I. du Pont de Nemours and Company | Fungicidal pyrazoles |
| US9617266B2 (en) | 2013-03-05 | 2017-04-11 | Merck Patent Gmbh | Imidazopyrimidine derivatives |
| US20160024071A1 (en) | 2013-03-15 | 2016-01-28 | Elan Pharmaceuticals, Llc | Inhibitors of lrrk2 kinase activity |
| JP6553589B2 (ja) | 2013-03-15 | 2019-07-31 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ピリミド−ジアゼピノン化合物および障害の治療方法 |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CN105358550B (zh) | 2013-05-10 | 2018-04-06 | 卡鲁斯治疗有限公司 | 组蛋白脱乙酰基酶抑制剂 |
| PE20161443A1 (es) | 2014-01-29 | 2017-01-06 | Glaxosmithkline Ip Dev Ltd | Compuestos |
| WO2015131005A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| EP3312164B1 (en) | 2014-03-28 | 2020-12-09 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
| WO2016033100A1 (en) | 2014-08-25 | 2016-03-03 | Salk Institute For Biological Studies | Novel ulk1 inhibitors and methods using same |
| CN105461694B (zh) | 2014-09-27 | 2019-05-24 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| KR20170090476A (ko) | 2014-12-05 | 2017-08-07 | 어레이 바이오파마 인크. | 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진 |
| EP3271336A1 (en) | 2015-03-19 | 2018-01-24 | E. I. du Pont de Nemours and Company | Fungicidal pyrazoles |
| JP2018135268A (ja) | 2015-06-05 | 2018-08-30 | 大日本住友製薬株式会社 | 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩 |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| WO2017087282A1 (en) | 2015-11-18 | 2017-05-26 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| WO2017100703A1 (en) | 2015-12-10 | 2017-06-15 | Colin Combs | Ems analogues of lyn/src-tyrosine kinase inhibitors |
| JP2018537502A (ja) | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| AU2017213628B2 (en) * | 2016-02-05 | 2021-07-29 | Denali Therapeutics Inc. | Inhibitors of receptor-interacting protein kinase 1 |
| PT3472153T (pt) | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2017
- 2017-06-15 PT PT177333069T patent/PT3472153T/pt unknown
- 2017-06-15 CN CN201780036925.3A patent/CN109311857B/zh active Active
- 2017-06-15 AU AU2017286653A patent/AU2017286653B2/en active Active
- 2017-06-15 KR KR1020197000749A patent/KR102553188B1/ko active Active
- 2017-06-15 MD MDE20190504T patent/MD3472153T2/ro unknown
- 2017-06-15 SM SM20210699T patent/SMT202100699T1/it unknown
- 2017-06-15 CR CR20180592A patent/CR20180592A/es unknown
- 2017-06-15 HR HRP20211923TT patent/HRP20211923T1/hr unknown
- 2017-06-15 WO PCT/US2017/037782 patent/WO2017218843A1/en not_active Ceased
- 2017-06-15 RS RS20211513A patent/RS62868B1/sr unknown
- 2017-06-15 PE PE2018003221A patent/PE20190395A1/es unknown
- 2017-06-15 SI SI201731005T patent/SI3472153T1/sl unknown
- 2017-06-15 CN CN202111282850.1A patent/CN114315819A/zh active Pending
- 2017-06-15 UA UAA201812165A patent/UA126231C2/uk unknown
- 2017-06-15 SG SG10201912632YA patent/SG10201912632YA/en unknown
- 2017-06-15 JO JOP/2018/0113A patent/JOP20180113B1/ar active
- 2017-06-15 JP JP2018565694A patent/JP7004459B2/ja active Active
- 2017-06-15 ES ES17733306T patent/ES2900368T3/es active Active
- 2017-06-15 IL IL299415A patent/IL299415B2/en unknown
- 2017-06-15 US US15/624,566 patent/US20170362206A1/en not_active Abandoned
- 2017-06-15 MX MX2018015630A patent/MX392230B/es unknown
- 2017-06-15 PL PL17733306T patent/PL3472153T3/pl unknown
- 2017-06-15 DK DK21198102.2T patent/DK3998261T3/da active
- 2017-06-15 ES ES21198102T patent/ES3036953T3/es active Active
- 2017-06-15 IL IL263484A patent/IL263484B2/en unknown
- 2017-06-15 TN TNP/2018/000422A patent/TN2018000422A1/en unknown
- 2017-06-15 KR KR1020247029993A patent/KR102843750B1/ko active Active
- 2017-06-15 LT LTEPPCT/US2017/037782T patent/LT3472153T/lt unknown
- 2017-06-15 KR KR1020237022665A patent/KR102705724B1/ko active Active
- 2017-06-15 SG SG11201810579YA patent/SG11201810579YA/en unknown
- 2017-06-15 HU HUE17733306A patent/HUE056678T2/hu unknown
- 2017-06-15 EP EP25174508.9A patent/EP4635570A2/en active Pending
- 2017-06-15 EP EP21198102.2A patent/EP3998261B1/en active Active
- 2017-06-15 CU CU2018000152A patent/CU24605B1/es unknown
- 2017-06-15 CR CR20220182A patent/CR20220182A/es unknown
- 2017-06-15 EP EP17733306.9A patent/EP3472153B1/en active Active
- 2017-06-15 IL IL299412A patent/IL299412B2/en unknown
- 2017-06-15 PE PE2023001478A patent/PE20240221A1/es unknown
- 2017-06-15 CA CA3025672A patent/CA3025672A1/en active Pending
- 2017-06-16 TW TW106120263A patent/TWI786049B/zh active
- 2017-10-25 US US15/793,882 patent/US9932325B2/en active Active
-
2018
- 2018-03-21 US US15/927,920 patent/US10590114B2/en active Active
- 2018-11-19 PH PH12018502427A patent/PH12018502427A1/en unknown
- 2018-12-13 MX MX2022005610A patent/MX2022005610A/es unknown
- 2018-12-13 SA SA518400660A patent/SA518400660B1/ar unknown
- 2018-12-13 MX MX2021010304A patent/MX2021010304A/es unknown
- 2018-12-13 DO DO2018000285A patent/DOP2018000285A/es unknown
- 2018-12-13 SA SA521430638A patent/SA521430638B1/ar unknown
- 2018-12-14 CL CL2018003597A patent/CL2018003597A1/es unknown
- 2018-12-14 EC ECSENADI201892481A patent/ECSP18092481A/es unknown
- 2018-12-14 CO CONC2018/0013585A patent/CO2018013585A2/es unknown
-
2019
- 2019-01-14 ZA ZA2019/00229A patent/ZA201900229B/en unknown
-
2020
- 2020-03-13 US US16/818,745 patent/US11111235B2/en active Active
-
2021
- 2021-08-13 US US17/401,833 patent/US11591316B2/en active Active
- 2021-12-14 CY CY20211101098T patent/CY1124789T1/el unknown
-
2022
- 2022-04-08 AU AU2022202372A patent/AU2022202372B2/en active Active
- 2022-04-25 DO DO2022000088A patent/DOP2022000088A/es unknown
-
2023
- 2023-01-19 US US18/099,082 patent/US11834439B2/en active Active
- 2023-04-17 DO DO2023000077A patent/DOP2023000077A/es unknown
-
2024
- 2024-06-14 US US18/744,133 patent/US20250034119A1/en active Pending
- 2024-07-03 AU AU2024204621A patent/AU2024204621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018013585A2 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para uso en el tratamiento de transtornos neurodegenerativos. | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| MX2016014166A (es) | Compuestos de triaminopirimidina utiles para evitar o tratar la malaria. | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| GT201700016A (es) | [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| AR099766A1 (es) | Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos | |
| CO2017000211A2 (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| EA201892532A1 (ru) | Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний | |
| UY36393A (es) | Síntesis de inhibidor de pi3k y sales del mismo | |
| MY195679A (en) | Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders | |
| SV2017005474A (es) | Nuevas formas sólidas de desvenlafaxina | |
| BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? |